二代测序提高恶性胆道狭窄检出率并改变临床管理
这项回顾性队列纳入77例ERCP期间行BiliSeq检测的胆道狭窄患者(28例恶性、49例良性),BiliSeq对恶性病变的敏感度为75%,高于细胞学与活检联合的42.9%(P=.03);两者联合后敏感度由42.9%提升至85.7%(P<.001)。在细胞学/活检阴性的恶性狭窄患者中,BiliSeq使75%的病例改变了临床管理。
要点
- BiliSeq对恶性胆道狭窄的敏感度为75%,高于细胞学与活检联合的42.9%。
- BiliSeq联合细胞学/活检后敏感度由42.9%提升至85.7%。
- 细胞学/活检阴性的恶性狭窄患者中,BiliSeq使75%的病例改变临床管理。
核心结论
- 二代测序(NGS)与病理评估联合可提高恶性胆道狭窄的检出敏感度,在病理结果阴性时使75%的病例改变临床管理。
研究设计与样本
- 回顾性队列研究,纳入77例在经内镜逆行胰胆管造影(ERCP)期间接受BiliSeq检测的胆道狭窄患者。
- 采用McNemar检验比较各检测方法的敏感度,并计算特异度、阳性预测值和阴性预测值。
- 临床影响定义为BiliSeq正确识别出细胞学/病理阴性的恶性胆道狭窄患者。
主要发现
- 77例患者中恶性28例、良性49例,原发性硬化性胆管炎24例(31.2%)。
- 恶性病例中检出肿物者占35.7%,良性病例中占6.1%(P=.001)。
- BiliSeq对恶性病变的敏感度为75%(95%CI,55.1%-89.3%),高于细胞学与活检联合的42.9%(95%CI,24.5%-62.8%;P=.03)。
- BiliSeq联合细胞学/活检后敏感度由42.9%提升至85.7%(P<.001)。
- 在细胞学/活检阴性的恶性狭窄患者(n=16)中,BiliSeq使75%的病例改变临床管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Malignant biliary strictures (MBSs) pose diagnostic and therapeutic challenges due to the frequent indeterminate results after initial sampling. A next-generation sequencing (NGS) panel (BiliSeq) offers promise in MBS detection, but real-world performance remains uncertain. This study aimed to assess standard sampling techniques alone and with BiliSeq for malignancy detection in biliary strictures and to evaluate management changes based on NGS. METHODS: This retrospective cohort study included 77 patients with biliary strictures undergoing BiliSeq during ERCP. Sensitivity, specificity, positive predictive values, and negative predictive values were calculated, and sensitivity was compared between tests by using the McNemar test. Clinical impact was defined by identifying MBS patients with negative cytology/pathology correctly identified by BiliSeq. RESULTS: Among 77 patients (28 malignant, 49 benign) who underwent BiliSeq testing during ERCP, primary sclerosing cholangitis was present in 24 patients (31.2%). A mass was detected in 35.7% of MBS cases versus 6.1% of benign cases (P = .001). BiliSeq sensitivity for malignancy was 75% (95% CI, 55.1%-89.3%), surpassing the combination of cytology and biopsy (42.9%; 95% CI, 24.5%-62.8%; P = .03). Combining BiliSeq with cytology/biopsy improved sensitivity from 42.9% to 85.7% (P < .001). Among MBS patients with negative cytology/biopsy findings (n = 16), BiliSeq altered management in 75%. CONCLUSIONS: NGS and pathologic evaluation enhanced MBS detection sensitivity, leading to management changes in 75% of cases when pathology test results were negative.
引用
- Bardhi O, Jones A, Ellis D, et al. Next-generation sequencing improves the detection of malignant biliary strictures and changes management. Gastrointest Endosc. 2024. PMID: 39716538. doi:10.1016/j.gie.2024.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。